ReutersNovo Nordisk confident of amycretin obesity drug launch this decadeRead full articleOops!Something went wrong.Please try again later.More content belowOops!Something went wrong.Please try again later.More content belowNOVO-B.CONVOMaggie Fick and Jacob Gronholt-PedersenUpdated March 8, 2024 at 8:54 PM·2 min read1 / 2Novo Nordisk confident of amycretin obesity drug launch this decadeNovo Nordisk’s Executive Vice President, Development, Martin Holst Lange talks to a journalist in CopenhagenIn this article: Oops!Something went wrong.Please try again later.More content belowOops!Something went wrong.Please try again later.More content belowNOVO-B.CO
Yahoo Finance 
